These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37368513)

  • 41. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
    Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
    Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T.
    Tang A; Dzyubak B; Yin M; Schlein A; Henderson WC; Hooker JC; Delgado TI; Middleton MS; Zheng L; Wolfson T; Gamst A; Loomba R; Ehman RL; Sirlin CB
    Eur Radiol; 2022 May; 32(5):2937-2948. PubMed ID: 34928415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
    Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
    Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
    Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M
    Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance.
    Cunha GM; Delgado TI; Middleton MS; Liew S; Henderson WC; Batakis D; Wang K; Loomba R; Huss RS; Myers RP; Sirlin CB; Fowler KJ; Hasenstab KA
    AJR Am J Roentgenol; 2022 Aug; 219(2):224-232. PubMed ID: 35107306
    [No Abstract]   [Full Text] [Related]  

  • 48. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
    Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
    Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Ajmera VH; Liu A; Singh S; Yachoa G; Ramey M; Bhargava M; Zamani A; Lopez S; Mangla N; Bettencourt R; Rizo E; Valasek M; Behling C; Richards L; Sirlin C; Loomba R
    Hepatology; 2020 Mar; 71(3):849-860. PubMed ID: 31556124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
    Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
    Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imaging biomarkers of NAFLD, NASH, and fibrosis.
    Ajmera V; Loomba R
    Mol Metab; 2021 Aug; 50():101167. PubMed ID: 33460786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Ajmera V; Park CC; Caussy C; Singh S; Hernandez C; Bettencourt R; Hooker J; Sy E; Behling C; Xu R; Middleton MS; Valasek MA; Faulkner C; Rizo E; Richards L; Sirlin CB; Loomba R
    Gastroenterology; 2018 Aug; 155(2):307-310.e2. PubMed ID: 29660324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.
    Chen J; Martin-Mateos R; Li J; Yin Z; Chen J; Lu X; Glaser KJ; Mounajjed T; Yashiro H; Siegelman J; Winkelmann CT; Wang J; Ehman RL; Shah VH; Yin M
    Alcohol Clin Exp Res; 2021 Oct; 45(10):2103-2117. PubMed ID: 34486129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Tamaki N; Munaganuru N; Jung J; Yonan AQ; Loomba RR; Bettencourt R; Ajmera V; Valasek MA; Behling C; Sirlin CB; Loomba R
    Gut; 2022 May; 71(5):983-990. PubMed ID: 33883248
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.